Navigation Links
Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
Date:5/17/2011

ATLANTA, May 17, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc. today announced the election Dr. Steven C. Gilman to the Board of Directors of Inhibikase Therapeutics, Inc.

(Logo: http://photos.prnewswire.com/prnh/20110517/CL02791LOGO)

Dr. Steven Gilman joined Cubist Pharmaceuticals in 2008 and currently serves as the Cubist's Executive Vice President, Research & Development and Chief Scientific Officer. Before joining Cubist Pharmaceuticals, Dr. Gilman held several positions with ActivBiotics, Inc., including Chairman of the board of directors and President and CEO. Previously Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Additionally, Dr. Gilman served as Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas.

Dr. Gilman currently serves on the Boards of Directors of the Massachusetts Biotechnology Association and the Massachusetts Society for Medical Research. In addition, Dr. Gilman serves on the Science and Regulatory Executive Committee of PhRMA. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.

Dr. Gilman joins Board members Dr. Stephen Fesik, Orrin H. Ingram, II Chair in Cancer Research at Vanderbilt University and former Vice-President for Cancer Research, Abbott Laboratories, Mr. David Gryska, former CFO of Celgene and Ms. Lisa Evren, Vice-President and Treasurer, Talisman-Energy.

"We are fortunate to add Dr. Gilman to the slate of new Board members elected in the last eight months.  Dr. Gilman's breadth of experience in pharmaceutical development and senior leadership will accelerate Inhibikase's growth and entry into the clinic on a novel platform," said Milton H. Werner, Ph.D., Inhibikase Therapeutics' President and Chief Executive Officer. "The Board is comprised of four leaders in research, development and finance whose insights will be of tremendous value as we build an innovative company and a novel treatment approach for infectious disease."

About Inhibikase Therapeutics, Inc.Inhibikase Therapeutics is transforming the way pharmaceuticals attack infectious diseases.  Its small molecule platform enables treatment of bacterial AND viral infectious disease through a common mechanism of action.  The Company's host-targeting strategy using clinically validated drugs and targets treat disease with a low likelihood of stimulating resistance.  Founded in 2008 and headquartered in Atlanta, Georgia, Inhibikase Therapeutics is developing treatments for orphan indications arising from polyomaviruses, such as progressive multifocal leukoencephalopathy (PML),as well as a broad range of respiratory infectious diseases, including influenza, pneumonia and respiratory syncitial virus (RSV).Contact:  Milton H. Werner, Ph.D.President and Chief Executive OfficerInhibikase Therapeutics, Inc.(917) 494-0831
'/>"/>

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
2. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
3. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
4. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
5. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
6. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
7. Echo Therapeutics Expands Into New Headquarters in Philadelphia
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
10. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
11. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 ... ... Forecast 2016-2026: Opportunities for Leading Companies – our new ... new report discusses issues and events affecting the Alzheimer,s ... qualitative analyses to answer these key questions: - How ...
(Date:1/19/2017)... , Jan. 19, 2017 Many patients don,t ... their medication when a pharmacy just a few blocks ...  To alleviate this problem Medicationdiscountcard.com has created ... see exactly how much their medication will cost at ... Easy Medicationdiscountcard.com takes ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA ... drugs market is expected to grow at a CAGR of ... of 38.7% in the second half of the forecast period. The ... 2016 to 2027. The market is estimated at $1,058 million in ... ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, 20 million ... freedom of recovery, they often feel shame for having struggled with an eating disorder ... In the workshop, “Rising Strong in Life After an Eating Disorder” -- to be ...
(Date:1/20/2017)... ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 ... the lift is mounted on wheels, it can be wheeled out of the way and ... fasten to the deck. "We have transformed the feedback from customers into specific enhancements and ...
(Date:1/20/2017)... ... ... Overseer at The House of Yahweh has posted a new publication this week pleading to ... time like no other and society needs to understand the only way to help make ... to sound like an old bible beater because religion has a bad rap these days ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Doctor C ... it attended the January ECRM trade show to continue the marketing and distribution of ... C supplement, known for providing 400 percent better absorption than traditional vitamin C supplements. ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company based ... school-aged children since the holiday season. , “It happens every year around this ... hugs and taking photos, which is the head-to-head gateway that lice need to spread.” ...
Breaking Medicine News(10 mins):